Late-onset neutropenia following ocrelizumab therapy for multiple sclerosis-Reference-Cited by-同舟云学术

Late-onset neutropenia following ocrelizumab therapy for multiple sclerosis

Published:2019-01-11 Issue:9 Volume:92 Page:435-436
ISSN:0028-3878
Container-title:Neurology
language:en
Short-container-title:Neurology

Author:

Cohen Bruce A.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Neurology (clinical)

Reference7 articles.

1. Ocrevus full prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761053lbl.pdf. Accessed July 3, 2018.

2. Rituximab-associated late-onset neutropenia: a case series and review of the literature;Monaco;Clin Rheumatol,2016

3. Late-onset Neutropenia in Patients with Rheumatoid Arthritis after Treatment with Rituximab

4. Late-onset neutropenia following rituximab treatment for rheumatologic conditions;Breuer;Clin Rheumatol,2014

5. Characteristics of late onset neutropenia in rheumatologic patients treated with rituximab: a case review analysis from a single center

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiple sclerosis treatment review for primary care providers;The Nurse Practitioner;2024-06-25

2. Disease-modifying therapies and hematological disorders: a systematic review of case reports and case series;Frontiers in Neurology;2024-06-18

3. Anti-CD20 monoclonal antibodies in multiple sclerosis: Rethinking the current treatment strategy;Revue Neurologique;2024-04

4. A Proposed Approach to Screening and Surveillance Labs for Patients With Multiple Sclerosis on Anti-CD20 Therapy;Neurology Clinical Practice;2024-02

5. A Case of Late-Onset Neutropenia in Relapsing-Remitting Multiple Sclerosis Following Ocrelizumab Therapy;Cureus;2024-01-05